c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9425-9434

  Zhang, Xiaoping ^a   Zhang, Liang ^b   Yang, Hongmei ^b   Huang, Xu ^b   Otu, Hasan ^c   Libermann, Towia A ^c   DeWolf, William C ^b   Khosravi Far, Roya ^c   Olumi, Aria F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Division of Urology   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLICE INHIBITORY PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEXATUMUMAB; MESSENGER RNA; PROTEIN C FOS; PROTEIN C JUN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION;

ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; RECOMBINANT PROTEINS; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35148829925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1310     Document Type: Article

References (45)

1. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-22.
2. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
3. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-7.
4. Johnson RL, Gillotte D, Poortman C, et al. Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by Taxol and carboplatin. Orlando (FL); American Association of Cancer Research Annual Meeting; 2004. Abstract 3579.
5. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9.
6. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-40.
7. Smeyne RJ, Vendrell M, Hayward M, et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993;363:166-9.
8. Marti A, Jehn B, Costello E, et al. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. Oncogene 1994;9:1213-23.
9. Preston GA, Lyon TT, Yin Y, et al. Induction of apoptosis by c-Fos protein. Mol Cell Biol 1996;16:211-8.
10. Zhang X, Jin TG, Yang H, Dewolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004;64:7086-91.
11. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
12. Ricci MS, Jin Z, Dews M, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-55.
13. Yang H, Lin CH, Ma G, Baffi MO, Wathelet MG. Interferon regulatory factor-7 synergizes with other transcription factors through multiple interactions with p300/CBP coactivators. J Biol Chem 2003;278:15495-504.
14. Tillman K, Oberfield JL, Shen XQ, Bubulya A, Shemshedini L. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine 1998;9:193-200.
15. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002;9:62-70.
16. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007;25:146-57.
17. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol 2002;2:S1-15.
18. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
19. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-305.
20. Gao S, Lee P, Wang H, et al. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005;19:1792-802.
21. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 1998;28:370-490.
22. Li W, Zhang X, Olumi AF. MG-132 Sensitizes TRAIL-resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Res 2007;67:2247-55.
23. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
24. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041-52.
25. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002;277:45162-71.
26. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-43.
27. Quan T, He T, Voorhees JJ, Fisher GJ. Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. J Biol Chem 2005;280:8079-85.
28. Tanos T, Marinissen MJ, Leskow FC, et al. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005;280:18842-52.
29. Manchester KM, Heston WD, Donner DB. Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J 1993;290:185-90.
30. Siegmund D, Mauri D, Peters N, et al. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway. J Biol Chem 2001;276:32585-90.
31. Drosopoulos KG, Roberts ML, Cermak L, et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005;280:22856-67.
32. Sassone-Corsi P, Sisson JC, Verma IM. Transcriptional autoregulation of the proto-oncogene fos. Nature 1988;334:314-9.
33. Lucibello FC, Lowag C, Neuberg M, Muller R. transrepression of themouse c-fos promoter: a novel mechanism of Fos-mediated trans-regulation. Cell 1989;59:999-1007.
34. Okada S, Obata S, Hatano M, Tokuhisa T. Dominant-negative effect of the c-fos family gene products on inducible NO synthase expression in macrophages. Int Immunol 2003;15:1275-82.
35. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 2003;171:4984-9.
36. Mackeigan JP, Murphy LO, Dimitri CA, Blenis J. Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells. Mol Cell Biol 2005;25:4676-82.
37. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 1994;371:171-5.
38. David JP, Mehic D, Bakiri L, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 2005;115:664-72.
39. Manak JR, de Bisschop N, Kris RM, Prywes R. Casein kinase II enhances the DNA binding activity of serum response factor. Genes Dev 1990;4:955-67.
40. Wang Y, Falasca M, Schlessinger J, et al. Activation of the c-fos serum response element by phosphatidyl inositol 3-kinase and rho pathways in HeLa cells. Cell Growth Differ 1998;9:513-22.
41. Acquaviva C, Bossis G, Ferrara P, Brockly F, Jariel-Encontre I, Piechaczyk M. Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci 2002;973:426-34.
42. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005;280:14507-13.
43. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
44. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002;21:3704-14.
45. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004;199:1513-22.